Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, Mansi; Marron, Thomas U.; Kodysh, Julia; Finnigan, John P.; Onkar, Sayali; Kaminska, Anna; Tuballes, Kevin; Guo, Ruiwei; Sabado, Rachel Lubong; Meseck, Marcia; O’Donnell, Timothy J.; Sebra, Robert P.; Parekh, Samir; Galsky, Matthew D.; Blasquez, Ana; Gimenez, Gustavo; Bicak, Mesude; Cimen Bozkus, Cansu; Delbeau-Zagelbaum, Daniela; Rodriguez, Denise; Acuna-Villaorduna, Ana; Misiukiewicz, Krzysztof J.; Posner, Marshall R.; Miles, Brett A.; Irie, Hanna Y.; Tiersten, Amy; Doroshow, Deborah B.; Wolf, Andrea; Mandeli, John; Brody, Rachel; Salazar, Andres M.; Gnjatic, Sacha; Hammerbacher, Jeff; Schadt, Eric; Friedlander, Philip; Rubinsteyn, Alexander; Bhardwaj, Nina

doi:10.1158/2159-8290.28918037

Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

journal contribution

posted on 2025-05-02, 07:22 authored by Mansi Saxena, Thomas U. Marron, Julia Kodysh, John P. Finnigan, Sayali Onkar, Anna Kaminska, Kevin Tuballes, Ruiwei Guo, Rachel Lubong Sabado, Marcia Meseck, Timothy J. O’Donnell, Robert P. Sebra, Samir Parekh, Matthew D. Galsky, Ana Blasquez, Gustavo Gimenez, Mesude Bicak, Cansu Cimen Bozkus, Daniela Delbeau-Zagelbaum, Denise Rodriguez, Ana Acuna-Villaorduna, Krzysztof J. Misiukiewicz, Marshall R. Posner, Brett A. Miles, Hanna Y. Irie, Amy Tiersten, Deborah B. Doroshow, Andrea Wolf, John Mandeli, Rachel Brody, Andres M. Salazar, Sacha Gnjatic, Jeff Hammerbacher, Eric Schadt, Philip Friedlander, Alexander Rubinsteyn, Nina Bhardwaj

Supplementary Fig1. PGV001 feasibility and recurrence free survival a) Survival plot depicting overall survival (OS). N=12. Median survival depicted by vertical dotted line b) Survival plot depicting recurrence free survival (RFS). Median RFS is depicted by vertical dotted line. N=12. c) Swimmer plot depicting time-line of clinical events for each patient since their curative intent treatment. d) Comparing linear correlation between TMB or neoantigen load vs OS at 60 months from 1st vaccine. Pearson correlation coefficient (r) calculated for fitting of the correlation with 95% confidence interval (95%CI). TMB: tumor mutation burden, NeoAg: neoantigens, OS: overall survival,

Funding

Lake Champlain Cancer Research Organization

Parker Institute for Cancer Immunotherapy (PICI)

History

ARTICLE ABSTRACT

The PGV001 platform is feasible, safe, and immunogenic. The OpenVax pipeline predicted immunogenic neoantigens in tumors with wide-ranging mutational burdens. Data from this study prompted three additional PGV001 trials, one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an ICI, and another in prostate cancer.